PT Millennium Pharmacon International Tbk (SDPC.JK)
IDR 129.0
(-0.77%)
IDR 129.0
(-0.77%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1361.96 Billion IDR | 19.2% |
| 2022 | 1142.59 Billion IDR | 17.87% |
| 2021 | 969.4 Billion IDR | 3.61% |
| 2020 | 935.62 Billion IDR | -6.01% |
| 2019 | 995.4 Billion IDR | 3.6% |
| 2018 | 960.78 Billion IDR | 32.45% |
| 2017 | 725.39 Billion IDR | 22.91% |
| 2016 | 590.16 Billion IDR | 18.29% |
| 2015 | 498.9 Billion IDR | 22.22% |
| 2014 | 408.2 Billion IDR | 14.4% |
| 2013 | 356.8 Billion IDR | 26.98% |
| 2012 | 280.98 Billion IDR | 22.87% |
| 2011 | 228.69 Billion IDR | 23.12% |
| 2010 | 185.74 Billion IDR | 3.91% |
| 2009 | 178.74 Billion IDR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1515.78 Billion IDR | -4.52% |
| 2024 Q3 | 1488.72 Billion IDR | -1.79% |
| 2024 Q1 | 1587.62 Billion IDR | 16.57% |
| 2023 FY | 1361.96 Billion IDR | 19.2% |
| 2023 Q3 | 1264.78 Billion IDR | 1.13% |
| 2023 Q1 | 1208.21 Billion IDR | 5.74% |
| 2023 Q4 | 1361.96 Billion IDR | 7.68% |
| 2023 Q2 | 1250.58 Billion IDR | 3.51% |
| 2022 Q2 | 1013.93 Billion IDR | -3.71% |
| 2022 Q3 | 1113.38 Billion IDR | 9.81% |
| 2022 FY | 1142.59 Billion IDR | 17.87% |
| 2022 Q4 | 1142.59 Billion IDR | 2.62% |
| 2022 Q1 | 1053.01 Billion IDR | 8.62% |
| 2021 Q2 | 1022.89 Billion IDR | 4.23% |
| 2021 Q1 | 981.34 Billion IDR | 4.89% |
| 2021 FY | 969.4 Billion IDR | 3.61% |
| 2021 Q4 | 969.4 Billion IDR | -16.3% |
| 2021 Q3 | 1158.18 Billion IDR | 13.23% |
| 2020 FY | 935.62 Billion IDR | -6.01% |
| 2020 Q2 | 980.97 Billion IDR | -8.76% |
| 2020 Q4 | 935.62 Billion IDR | -0.5% |
| 2020 Q1 | 1075.18 Billion IDR | 8.02% |
| 2020 Q3 | 940.33 Billion IDR | -4.14% |
| 2019 Q2 | 1053.98 Billion IDR | 0.66% |
| 2019 FY | 995.4 Billion IDR | 3.6% |
| 2019 Q4 | 995.4 Billion IDR | -2.9% |
| 2019 Q1 | 1047.07 Billion IDR | 8.98% |
| 2019 Q3 | 1025.12 Billion IDR | -2.74% |
| 2018 Q2 | 790.76 Billion IDR | 14.87% |
| 2018 FY | 960.78 Billion IDR | 32.45% |
| 2018 Q4 | 960.78 Billion IDR | 9.61% |
| 2018 Q3 | 876.58 Billion IDR | 10.85% |
| 2018 Q1 | 688.37 Billion IDR | -5.1% |
| 2017 Q2 | 701.77 Billion IDR | 17.58% |
| 2017 Q4 | 725.39 Billion IDR | 2.09% |
| 2017 Q3 | 710.54 Billion IDR | 1.25% |
| 2017 FY | 725.39 Billion IDR | 22.91% |
| 2017 Q1 | 596.86 Billion IDR | 1.13% |
| 2016 Q1 | 491.48 Billion IDR | -1.49% |
| 2016 FY | 590.16 Billion IDR | 18.29% |
| 2016 Q2 | 608.84 Billion IDR | 23.88% |
| 2016 Q3 | 575.52 Billion IDR | -5.47% |
| 2016 Q4 | 590.16 Billion IDR | 2.54% |
| 2015 Q3 | 479.71 Billion IDR | -3.17% |
| 2015 Q1 | 420.36 Billion IDR | 2.98% |
| 2015 FY | 498.9 Billion IDR | 22.22% |
| 2015 Q4 | 498.9 Billion IDR | 4.0% |
| 2015 Q2 | 495.44 Billion IDR | 17.86% |
| 2014 Q3 | 388.61 Billion IDR | 17.61% |
| 2014 FY | 408.2 Billion IDR | 14.4% |
| 2014 Q4 | 408.2 Billion IDR | 5.04% |
| 2014 Q1 | 307.62 Billion IDR | -13.78% |
| 2014 Q2 | 330.43 Billion IDR | 7.42% |
| 2013 Q4 | 356.8 Billion IDR | 9.77% |
| 2013 Q1 | 269.76 Billion IDR | -3.99% |
| 2013 Q3 | 325.04 Billion IDR | 9.49% |
| 2013 Q2 | 296.88 Billion IDR | 10.05% |
| 2013 FY | 356.8 Billion IDR | 26.98% |
| 2012 Q4 | 280.98 Billion IDR | 8.4% |
| 2012 Q3 | 259.2 Billion IDR | 0.0% |
| 2012 FY | 280.98 Billion IDR | 22.87% |
| 2011 FY | 228.69 Billion IDR | 23.12% |
| 2010 FY | 185.74 Billion IDR | 3.91% |
| 2009 FY | 178.74 Billion IDR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| PT Enseval Putera Megatrading Tbk. | 3658.01 Billion IDR | 62.768% |
| PT Itama Ranoraya Tbk | 599.68 Billion IDR | -127.114% |
| PT Kimia Farma (Persero) Tbk | 11418.56 Billion IDR | 88.072% |
| PT Soho Global Health Tbk | 2347.86 Billion IDR | 41.991% |